New combo attack on tough prostate cancer
NCT ID NCT07451795
Summary
This study is testing whether adding a new immunotherapy drug called SHR-1701 to precise, high-dose radiation (SBRT) can better control advanced prostate cancer that has spread and stopped responding to standard hormone therapy. It will involve about 66 men whose cancer has progressed despite prior treatments. The main goal is to see if this combination can delay the cancer's growth for longer than current options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Fudan University Shanghai Cancer Center Xiamen Branch
RECRUITINGXiamen, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Fujian Cancer Hospital
RECRUITINGFujian, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.